Table 2.
Clinical trials of PARP1 inhibitors.
| PARP1 Inhibitor | Cancer Type | NCT Number * |
|---|---|---|
| Lynparza/Olaparib | Ovarian Cancer Breast Cancer |
NCT04041128 NCT04826198 NCT04774406 NCT03462342 NCT04065269 NCT03150576 NCT04582552 NCT04774406 |
| Cyh33 | Ovarian Cancer Breast Cancer Solid Tumor Prostate Cancer Endometrial Cancer |
NCT04586335 |
| Talazoparib | Neuroendocrine Tumors | NCT05053854 |
| Rp12146 | Solid Tumor Lung Cancer Breast Cancer Ovarian Cancer |
NCT05002868 |
| Niraparib | Advanced Solid Tumors (Excluding Prostate Cancer) Ovarian Cancer Head And Neck Squamous Cell Carcinoma |
NCT04267939 NCT04826198 NCT04774406 NCT04734665 NCT04681469 NCT04837209 NCT04774406 |
| Idx-1197 | Solid Tumors | NCT04174716 |
| Talazoparib | Breast Cancer |
NCT03990896 NCT04774406 |
| Rucaparib | Solid Tumor |
NCT04276376 NCT04774406 |
| Veliparib | Solid Tumors Liver Tumors Lymphomas Prostate Cancer |
NCT01434316 NCT01618357 |
* These data were obtained from https://www.clinicaltrials.gov/ (accessed on 30 December 2021). NCT, National Clinical Trial number.